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CASE REPORTS
Somatostatin treatment of a persistent
chyloperitoneum following abdominal aortic
surgery
Saziye Karaca, MD, Gino Gemayel, MD, and Afksendiyos Kalangos, MD, PhD, Geneva, Switzerland
Chyloperitoneum is an uncommon but serious complication of abdominal aortic surgery. There are no optimal guidelines
for the management of chyloperitoneum. We present here our experiences regarding the treatment of chyloperitoneum
with somatostatin for three patients who underwent surgery for abdominal aortic disease. Milky, odorless liquid was
observed in the abdominal drain of these patients. The conservative treatment with total parenteral nutrition failed;
therefore, in parallel, we initiated a somatostatin treatment as a continuous perfusion. Drain loss decreased in all up to the
second day of treatment. The probable mechanisms of the somatostatin decrease the intestinal absorption of fats via the
specific receptors, decrease triglyceride concentration in the thoracic duct, and attenuate lymph flow in the major
lymphatic channels. The presented cases showed successful treatment using somatostatin and may be a new generation of
effective treatments for chyloperitoneum. (J Vasc Surg 2012;56:1409-12.)
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(Chyloperitoneum (chylous ascites) is a rare complica-
tion of abdominal and thoracic surgery.1,2 It is defined as
the accumulation of chylomicron-rich lymphatic milky ef-
fusions in the abdominal cavity. Chyloperitoneum after
aortic surgery is the result of the disruption of the lymphatic
system that occurs between the cistern chili (the cisterna
chyli3 is found on the posterolateral edge to the right of the
aorta) and the adjacent major lymphatic trunks in the
abdominal cavity because of traumatic injury or obstruc-
tion.4 The previously reported mortality from chyloperito-
neum after abdominal aortic surgery is 11% to 18%. The
main reason for death is sepsis, pulmonary embolism, and
malnutrition.5 Rapid diagnosis of the effusion is the most
important part of management. The consequence of delay
induces critical losses of fluid, lymph, lymphocytes, pro-
teins, coagulation factors, and immune deficiencies, which
increase the prevalence of morbidity and mortality.6,7
Chyloperitoneum has been defined by mean white
blood cell counts 5000/mL. Chyloperitoneum is signif-
icantly constituted by triglyceride (TG) concentration
1.24 mmol/L, high albumin (30 g/L), high numbers of
immunoglobulin molecules, and high numbers of lympho-
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http://dx.doi.org/10.1016/j.jvs.2012.05.004ytes.7 The TG level is an important diagnostic tool, and
he concentration must be two to eight times higher in
hyloperitoneum fluid than in plasma.8
There is no consensus regarding the optimal treatment
f chyloperitoneum. Conservative treatments such as low-
at diets containing medium-chain TG molecules or total
arenteral nutrition (TPN) have shown slow effects with-
ut assurance of cure.9,10 This study focuses on three
atients who postoperatively developed chyloperitoneum
nd who showed good responses to somatostatin therapy.
ASE REPORTS
Case 1. An 83-year-old female underwent surgery for an
neurysm in the abdominal aorta performed by midline transab-
ominal approach. An aorto-aortic bypass was undertaken with a
acron graft, and an abdominal passive drain (Blake-type drains;
thicon, San Angelo, Tex) was placed on the left retroperitoneal
issected space. A significant volume of milky effusion was ob-
erved through the abdominal drain over the following days
400 mL/d) despite continued TPN, but without success. Mi-
roscopic and biochemical analyses of this drain fluid revealed TG
8.7 mmol/L; high levels of albumin and a predominance of
ymphocytes (87%) established the diagnosis. In the presence of
ncreasing drain losses under conservative treatment (TPN), we
dministered somatostatin as a continuous perfusion11 up to 9 days
fter surgery, and thereafter followed the somatostatin protocol
escribed below.
Case 2. A 68-year-old male underwent an aortobifemoral
ypass performed by midline transabdominal approach. Abdomi-
al passive drain (Blake Silicone; Ethicon) was placed on the left
etroperitoneal dissected space. Postoperatively, the drainage
bloody/milky) increased over the few days to 250 mL/24 h.
nalyses of this drain fluid revealed a TG 6.1 mmol/L, high
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November 20121410 Karaca et allevels of albumin, and lymphocytes up to 60%; the diagnosis of
chyloperitoneum was confirmed. The patient was under TPN, but
without success, and drainage loss continued in significant quan-
tities. We started somatostatin therapy as a continuous perfusion
up to 5 days after surgery.11
Case 3. An 18-year-old male underwent surgery for coarcta-
tion of the thoracoabdominal area by lateral thoracotomy and
midline transabdominal approach. Replacement of the thoracoab-
domen was undertaken with a Dacron prosthesis. Passive drains
were placed on the left pleura and left retroperitoneal dissected
space (Blake Silicone). The pleural drain could be removed after 2
days, but the peritoneal drain showed a milky loss of 250 mL/d
on the third postoperative day. Although the patient was under
TPN, but without success, the drain loss decreased to 400 mL/24
h on the fifth postoperative day. Analyses of this drain fluid revealed
a TG level 4.3 mmol/L, high levels of albumin, and a predom-
inance of lymphocytes (68%), thereby establishing the diagnosis of
chyloperitoneum. On the same day, somatostatin was adminis-
tered as a continuous perfusion.11
Protocol of somatostatin treatment. Somatostatin (3.5
g/kg/h) was administered as a continuous perfusion on the first
day of treatment. The somatostatin dosage was increased to 0.5
g/kg/h per day after 24 hours if no side effects were manifested,
until the drain loss decreased to 100 mL/d. Somatostatin treat-
Fig 1. Volume of chylous effusion drained (mL/d) in
Fig 2. Volume of chylous effusion drained (mL/d) inment was terminated for 24 hours before removing the perito- teal drain. During the somatostatin treatment, we continued in all
ases the TPN. At the end of the somatostatin treatment, we
ecreased the TPN, and the patients started slowly with an oral
at-free diet for the long term (4 weeks).
ISCUSSION
The mean number of days after surgery at which soma-
ostatin therapy was started in our cases was 6.3 days
range, 5-9 days). The three patients were under TPN for a
ean of 5.3 days (range, 5-6 days) without successful
esolution of chyloperitoneum. The minimum dosage of
omatostatin at treatment commencement was 3.5 g/
g/h. The maximum dosage of somatostatin at treatment
ermination was 6.0 g/kg/h (Figs 1-3). The mean dura-
ion of somatostatin treatment was 6.6 days (range, 6-7
ays). The mean somatostatin dose was 7.5 g/kg/h.
ith increasing of somatostatin dosage, the drain loss
ecreased in all cases (150-200 mL/24 h) up to the second
ay of treatment (Figs 1-3). The retroperitoneal drain
ould be removed after a mean of 14 days postoperatively
range, 12-17 days) when the drain loss was50mL/24 h.
he mean total stay in hospital was 19 days (range, 14-23
ays). No side effects were observed during somatostatin
ion to the somatostatin therapy (g/kg/h) in case 1.
ion to the somatostatin therapy (g/kg/h) in case 2.reatment. At the 4-week, 3-month, and 6-month follow-
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Volume 56, Number 5 Karaca et al 1411ups, the patients underwent computed tomography imag-
ing of the abdomen, which showed no chyloperitoneum
residue.
Chylous effusionsmust be differentiated frompus, ascites,
and pseudochylous.12 Pseudochylous is a milky effusion that
mimics chyle, associated with decreased lipid-cholesterol or
lecithin-globulin complexes, seen in tuberculosis, chronic pul-
monary effusions, rheumatoid arthritis, or empyema.13
The first post-traumatic chyloperitoneum was de-
scribed by Goldmann 1921.14 Only 38 cases showing the
development of chyloperitoneum after aortic abdominal
surgery have been reported. Initial treatment with diuretics
and TPN followed by low-fat diets containing medium-
chain TG molecules is known.15 In 1990, Ulibarri et al
were the first to successfully treat chylothorax with soma-
tostatin.16 In 2009, Lumbreras et al reported that soma-
tostatin showed a positive response in 73% of patients
compared with 43% of patients with fat-free diets or diets
rich in medium-chain TG molecules.17-20 The mechanism
by which somatostatin and its analog octreotide stop chy-
lous effusions is not fully understood. The decrease of
intestinal absorption of fats via specific receptors reduces
triglyceride concentration in the thoracic duct and attenu-
ates lymph flow in the major lymphatic channels.21 It may
be related to the inhibitory effects of somatostatin on
lymphatic duct movement, and it also decreases the portal
pressure and visceral blood flow.22
Side effects may include increased blood glucose, diar-
rhea, dizziness, gastrointestinal bleeding, hepatotoxicity,
thrombocytopenia, respiratory failure, and disturbance of car-
diac rhythm. Similarly, treatment with the somatostatin ana-
log octreotide has been reported to show good results.23-26
If all conservative and pharmacologic treatments fail,
the surgical procedure is to close lymphatic fistulae. The
surgical application of a peritoneovenous shunt (LeVeen
shunt)27 was also reported; however, these types of inter-
ventions appear to have a high prevalence of complications,
mortality, and morbidity.27-30
CONCLUSIONS
There are no evidence-based guidelines for the man-
agement of chyloperitoneum. Somatostatin may be a new
Fig 3. Volume of chylous effusion drained (mL/d) ingeneration of effective treatments for chyloperitoneum tovoid long-term dietary restrictions, high-risk surgery, and
rolonged hospitalization. Surgical ligation of the injured
ymphatic channel should be performed only if conservative
herapy with TPN, fat-free, medium-chain TG diets, and
omatostatin treatment has failed in the first postoperative
eriod.
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